Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia.

abstract：:In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment...

journal_title：Leukemia & lymphoma

authors： Bengió RM,Riva ME,Moiraghi B,Lanari E,Milone J,Ventriglia V,Bullorsky E,Tezanos Pinto Md,Murro H,Bianchini M,Larripa I

更新日期：2011-09-01 00:00:00

abstract：:Recombinant interferon alpha-2b (IFN-alpha2) has direct and indirect antiproliferative effects in lymphoma, and may augment cytotoxicity when combined with chemotherapy. CALGB 8691 is a randomized study of daily oral cyclophosphamide (CPA) at 100 mg/m2 with or without IFN-alpha2 at 2 x 106 IU/m2 three times per week, ...

journal_title：Leukemia & lymphoma

authors： Smith SM,Johnson J,Cheson BD,Canellos G,Petroni G,Oken M,Duggan D,Hurd D,Gockerman JP,Parker B,Prchal J,Peterson BA,Cancer and Leukemia Group B.,Eastern Cooperative Oncology Group.

更新日期：2009-10-01 00:00:00

abstract：:Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...

journal_title：Leukemia & lymphoma

authors： Lilleyman JS

更新日期：1998-11-01 00:00:00

abstract：:Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...

journal_title：Leukemia & lymphoma

authors： Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

更新日期：2017-08-01 00:00:00

abstract：:Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...

journal_title：Leukemia & lymphoma

authors： Vacca A,Ribatti D,Roncali L,Dammacco F

更新日期：1995-12-01 00:00:00

abstract：:Renal involvement in patients with lymphoma is rare but associated with poor prognosis. We analyzed characteristics and outcome of 22 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and renal involvement treated with a rituximab-containing regimen in curative intent. The majority of patients presen...

journal_title：Leukemia & lymphoma

authors： Lehners N,Krämer I,Schwarzbich MA,Ho AD,Witzens-Harig M

更新日期：2016-11-01 00:00:00

abstract：:Neurological symptoms can represent the first clinical manifestation of central nervous system (CNS) involvement in Hodgkin lymphoma (HL). Because of its rarity, it is often misunderstood for other pathological processes. We report two cases of pediatric CNS HL, presenting with neurological symptoms at diagnosis. We h...

journal_title：Leukemia & lymphoma

authors： Burnelli R,Fabbri E,Guerrini G,Sperlì D,D'ambrosio A

更新日期：2011-06-01 00:00:00

abstract：:Myeloproliferation, myeloaccumulation (decreased apoptosis), inflammation, bone marrow fibrosis and angiogenesis are cardinal features of the Philadelphia-negative chronic myeloproliferative neoplasms: essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Histone deacetylases (HDACs) ...

journal_title：Leukemia & lymphoma

authors： Skov V,Larsen TS,Thomassen M,Riley CH,Jensen MK,Bjerrum OW,Kruse TA,Hasselbalch HC

更新日期：2012-01-01 00:00:00

abstract：:The short segments of cDNA encoding glycoprotein (GP)Ib alpha, GPIIb, GPIIIa and platelet factor (PF) 4 were amplified using reverse transcriptase-polymerase chain reaction (RT-PCR) in order to characterize various types of megakaryoblasts. Cell lines with megakaryocytic features (K562, CMK and HEL) were tested. GPIb ...

journal_title：Leukemia & lymphoma

authors： Yasunaga M,Ryo R,Sugano W,Yamaguchi N

更新日期：1992-08-01 00:00:00

abstract：:Fusarium infection is rare but important infection after bone marrow transplantation (BMT). A 27-year-old man developed systemic fusarial infection following severe skin damage probably caused by high-dose thiotepa administration. Systemic fusariosis rapidly progressed to a variety of organs despite antifungal treatme...

journal_title：Leukemia & lymphoma

authors： Miyazaki M,Miyakoshi S,Kami M,Mori M,Kishi Y,Inagawa H,Machida U,Matsumura T,Kawagoe S,Ueyama J,Morinaga S,Matsushita H,Muto Y

更新日期：2001-01-01 00:00:00

abstract：:Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limite...

journal_title：Leukemia & lymphoma

authors： Lester R,Li C,Phillips P,Shenkier TN,Gascoyne RD,Galbraith PF,Vickars LM,Leitch HA

更新日期：2004-09-01 00:00:00

abstract：:Myelofibrosis (MF), including primary, post-essential thrombocythemia and post-polycythemia vera MF, associates with a reduced quality of life and shortened life expectancy. Dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is prominent, even in the absence of the ...

journal_title：Leukemia & lymphoma

authors： Stein BL,Cervantes F,Giles F,Harrison CN,Verstovsek S

更新日期：2015-01-01 00:00:00

abstract：:Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

journal_title：Leukemia & lymphoma

authors： Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

更新日期：2000-06-01 00:00:00

abstract：:Abstract Reconstitution, engraftment kinetics and tumor cell clearance were analyzed after reduced intensity conditioning hematopoietic cell transplant (RIC-HCT) in patients with chronic lymphocytic leukemia (CLL). Patients were transplanted from unrelated (n = 40) or related (n = 10) donors after fludarabine and 2 Gy...

journal_title：Leukemia & lymphoma

authors： Hebenstreit K,Iacobelli S,Leiblein S,Eisfeld AK,Pfrepper C,Heyn S,Vucinic V,Franke GN,Krahl R,Fricke S,Becker C,Pönisch W,Behre G,Niederwieser D,Lange T

更新日期：2014-06-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

journal_title：Leukemia & lymphoma

authors： Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

更新日期：2004-08-01 00:00:00

abstract：:In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

journal_title：Leukemia & lymphoma

authors： Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

更新日期：2012-01-01 00:00:00

abstract：:Hodgkin lymphomas are characterised by the presence of rare malignant cells in a background of non-neoplastic inflammatory cells. Flow cytometric analysis of involved tissues is generally not thought to be useful in establishing the diagnosis, because of the small number of neoplastic cells present. However, two recen...

journal_title：Leukemia & lymphoma

authors： Rahemtullah A,Harris NL,Dorn ME,Preffer FI,Hasserjian RP

更新日期：2008-10-01 00:00:00

abstract：:The purpose of this study was to explore the characteristics and functions of BH3-only proteins Puma, Noxa and Bim in the prognosis, therapy and drug resistance of chronic lymphocytic leukemia (CLL). Puma, Noxa and Bim mRNAs were evaluated by real-time quantitative reverse transcriptase-polymerase chain reaction, and ...

journal_title：Leukemia & lymphoma

authors： Zhu HJ,Liu L,Fan L,Zhang LN,Fang C,Zou ZJ,Li JY,Xu W

更新日期：2013-12-01 00:00:00

abstract：:HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression...

journal_title：Leukemia & lymphoma

authors： Meyer A,Staratschek-Jox A,Springwald A,Wenk H,Wolf J,Wickenhauser C,Bullerdiek J

更新日期：2008-06-01 00:00:00

abstract：:Radioimmunotherapy using (90)Y-ibritumomab tiuxetan has predominantly been used in patients with follicular lymphoma, but little is known about its activity in patients with extranodal marginal zone lymphoma of the mucosa associated lymphoid tissue (MALT). A total of six patients progressing/relapsing following conven...

journal_title：Leukemia & lymphoma

authors： Hoffmann M,Troch M,Eidherr H,Traub-Weidinger T,Jonak C,Muellauer L,Raderer M

更新日期：2011-01-01 00:00:00

abstract：:We investigated CD25 expression in older (≥60 years) patients with new acute myelogenous leukemia treated with decitabine and plerixafor. Patients resistant to therapy or survival ≤1 year had significantly higher percentages of CD25pos myeloid blasts in baseline bone marrow. CD25pos patients had an increased odds of r...

journal_title：Leukemia & lymphoma

authors： Allan JN,Roboz GJ,Askin G,Ritchie E,Scandura J,Christos P,Hassane DC,Guzman ML

更新日期：2018-04-01 00:00:00

abstract：:Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. However, cytopenias...

journal_title：Leukemia & lymphoma

authors： Bose P,Verstovsek S

更新日期：2020-08-01 00:00:00

abstract：:We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

journal_title：Leukemia & lymphoma

authors： Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

更新日期：2002-02-01 00:00:00

abstract：:Elevated serum free light chains (FLCs) have been associated with an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to determine the clinical relevance of a quantitative assessment of intact circulating immunoglobulin (Ig), using serum Ig heavy chain/light chain pair (HLC) me...

journal_title：Leukemia & lymphoma

authors： Jardin F,Delfau-Larue MH,Molina TJ,Copie-Bergman C,Brière J,Petrella T,Canioni D,Fabiani B,Jais JP,Figeac M,Leroy K,Mareschal S,Salles GA,Coiffier B,Delarue R,Peyrade F,Bosly A,André M,Ketterer N,Haioun C,Tilly H

更新日期：2013-09-01 00:00:00

abstract：:The purpose of this study was to determine the activity of topotecan given by 21-day continuous infusion in patients previously treated with one prior therapy for a diffuse large-cell lymphoma or immunoblastic lymphoma. Patients with appropriate histology and measurable disease who had been treated with one prior chem...

journal_title：Leukemia & lymphoma

authors： Wiernik PH,Li H,Weller E,Hochster HS,Horning SJ,Nazeer T,Gordon LI,Habermann TM,Minniti CJ Jr,Shapiro GR,Cassileth PA

更新日期：2012-06-01 00:00:00

abstract：:The prognostic importance of inhomogeneities on magnetic resonance imaging (MRI) in non-Hodgkin lymphomas (NHL) was evaluated. Forty-six consecutive patients with high-grade NHL were examined and, for comparison purposes, 13 patients with low-grade NHL. The degree of inhomogeneity was measured with a quantitative meth...

journal_title：Leukemia & lymphoma

authors： Rehn SM,Rodriguez M,Bergström SR,Nyman RS,Glimelius BL

更新日期：1997-02-01 00:00:00

abstract：:Factors predictive for central nervous system (CNS) involvement at presentation were investigated in 152 patients with non-Hodgkin's lymphoma (NHL) except for lymphoblastic cell lymphoma and small noncleaved cell lymphoma. Twelve patients developed CNS involvement during their disease course. The incidence was 7.9% of...

journal_title：Leukemia & lymphoma

authors： Tomita N,Kodama F,Sakai R,Koharasawa H,Hattori M,Taguchi J,Fujita H,Tanabe J,Fujisawa S,Fukawa H,Harano H,Kanamori H,Miyashita H,Matsuzaki M,Ogawa K,Motomura S,Maruta A,Ishigatsubo Y

更新日期：2000-07-01 00:00:00

abstract：:The percentage of blasts in the bone marrow aspirates at day 7 or 14 of induction therapy in pediatric ALL patients is an indicator of rapid early response and an independent prognostic factor for long term outcome. Discrepancies between the percentages of blasts in bone marrow aspirates compared to biopsies have been...

journal_title：Leukemia & lymphoma

authors： Countouriotis A,Landaw EM,Naeim F,Moore TB,Sakamoto KM

更新日期：2004-04-01 00:00:00

abstract：:Renal lymphoma usually is a manifestation of disseminated disease and often is asymptomatic. Occasionally, the kidney(s) may be the major or only demonstrable site of disease, which may then present with a variety of urologic symptoms. The imaging studies should be tailored according to the presenting symptoms and pri...

journal_title：Leukemia & lymphoma

authors： Eisenberg PJ,Papanicolaou N,Lee MJ,Yoder IC

更新日期：1994-12-01 00:00:00

abstract：:The modern treatment of acute myelogenous leukemia (AML), consists of a polychemotherapeutic induction treatment followed by a post-remission therapy of variable intensity and duration and acute promyelocytic leukemia (APL) does not differ from this behavior. However, differently from the other AML subtypes, APL shows...

journal_title：Leukemia & lymphoma

authors： Avvisati G,Petti MC,Mandelli F

更新日期：1993-01-01 00:00:00